Emyria Limited (ASX:EMD)
Australia · Delayed Price · Currency is AUD 0.0480
+0.0010 (2.13%)
Sep 18, 2025, 11:35 AM AEST
Emyria Revenue
In the fiscal year ending June 30, 2025, Emyria had annual revenue of 1.39M AUD, down -36.68%. Emyria had revenue of 736.55K in the half year ending June 30, 2025, a decrease of -14.39%.
Revenue
1.39M
Revenue Growth
-36.68%
P/S Ratio
22.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
31.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.39M | -807.97K | -36.68% |
| Jun 30, 2024 | 2.20M | 610.25K | 38.32% |
| Jun 30, 2023 | 1.59M | -229.93K | -12.62% |
| Jun 30, 2022 | 1.82M | -153.51K | -7.77% |
| Jun 30, 2021 | 1.98M | 962.46K | 94.97% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |